Society

China's Sinovac COVID-19 vaccine proves effective in Brazil trials, but does not disclose numbers

On Tuesday Butantan Institute presented the efficacy rate numbers to Sinovac that requested to not disclose the rate because it needs to analyze each of the cases to apply to the China's health regulator

The Head of Butantan Institute, Dimas Covas. Photo: YouTube/Screenshot
  • Sinovac requested the transfer of Brazil’s database so it can make the analysis and present the data;
  • It has 15 days to present it. According to Butantan Institute, the application of the doses probably won’t delay from January 25.

Chinese vaccine maker Sinovac‘s COVID-19 vaccine (CoronaVac) has shown to be effective in late-stage trials in Brazil, but according to Brazil’s Butantan Institute, even though the efficacy data threshold of 50% was met, which allows the process of requesting emergency use in Brazil and China, the number was not disclosed due to a Sinovac request.

On Tuesday Butantan Institute presented the efficacy rate numbers to Sinovac that requested to not disclose the rate because it needs to analyze each of the cases to apply to the China’s health regulator.

READ ALSO: Russia says Sputnik V coronavirus vaccine approved for use in Argentina

According to Dimas Covas, the Head of Butantan Institute, Sinovac requested the transfer of Brazil’s database so it can make the analysis and present the data. According to Covas, Sinovac has 15 days for the analysis to take place. “I do not doubt that that date will be brought forward,” he added.

Brazil is the first country to complete late-stage trials of CoronaVac, and Butantan Institute already has deals to provide the vaccine to other Latin America countries, except Chile, that already has a deal with Sinovac. Argentina also expects to close a deal with Sinovac soon.

READ ALSO: Oxford-AstraZeneca vaccine to arrive in Brazil in February, says President of Brazil’s Fiocruz Institute

According to Covas on Thursday Brazil will receive 5 million doses of the CoronaVac vaccine, 3.4 million to be produced in Butantan, and 2.1 million already ready. Next week São Paulo is set to receive another 2 million doses.

“Data corroborate what we already know that the vaccine is certainly safer than all that is being tested at the moment, excellent safety profile, mild adverse events, very low frequency, a most common reaction was pain at the injection site. And even that injection was not substantially different between the group that received it and the placebo,” he stated.

Get the best insights about Latin America market in your inbox